AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02864147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine
Description: All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
Study NCT02864147 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imiquimod
Description: At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
Study NCT02864147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imiquimod
Description: At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
Study NCT03289416 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: Pure PRP II
Description: The Pure PRP II system will be used to collect and concentrate blood into platelet rich plasma that will be injected into the knee.
Study NCT03289416 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: OTHER
Intervention: PureBMC
Description: The PureBMC system will be used to collect and concentrate bone marrow aspirate into bone marrow concentrate that will be injected into the knee.
Study NCT01170923 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FDR-PET
Description: FDR-PET performed after 1 cycle of chemotherapy
Study NCT01170923 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT
Description: CT performed after 3 cycles of chemotherapy
Study NCT03045302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIM23B065
Description: Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).
Study NCT04219917 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio Tape
Description: Kinesio Tape will be applied to treat the pain associated with patellar tendonitis, to treat the cause of the pain, and to treat both factors.
Study NCT01395914 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anamorelin HCl
Study NCT01395914 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02251197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIII 890 CL
Study NCT02251197 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02517125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transoral robotic-assisted surgery with Da Vinci Xi
Study NCT02920021 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etokimab
Description: Humanized monoclonal antibody, administered by intravenous infusion
Study NCT02920021 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by intravenous infusion
Study NCT04300452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbetocin
Description: Administration of Carbetocin after placental detachment
Study NCT04300452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ergometrine Maleate
Description: Administration of ergometrin after placental detachment
Study NCT05143008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART Intervention
Description: Counseling sessions will be conducted by research project staff that has, at least, masters level or equivalent degrees. Sessions will occur up to 10 times at their regularly scheduled obstetric appointments and also weekly by phone and text messages. In person sessions will last approximately 20-30 minutes.
Study NCT04208321 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be supplied as matching tablets (to 40 mg and 80 mg VT-1598 tablets) containing the inactive components of VT-1598.
Study NCT02863913 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PD-1 Knockout T Cells
Description: PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
Study NCT02863913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
Study NCT02863913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.~Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant).
Study NCT02863913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IL-2
Description: Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).
Study NCT02863913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).
Study NCT01673100 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Promotion Intervention
Description: Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
Study NCT03053635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TLD1433 infusion and photodynamic therapy (PDT) treatment
Description: TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).
Study NCT01228305 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to \<2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
Study NCT01228305 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to \<2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
Study NCT03688022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-7117
Description: MT-7117
Study NCT03688022 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PPI
Description: Proton pump inhibitor
Study NCT03688022 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Acidic beverage
Description: Acidic beverage
Study NCT00410423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib with mitoxantrone, etoposide and cytarabine
Description: All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
Study NCT00410423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.0mg/m^2
Description: All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
Study NCT00410423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3mg/m^2
Description: All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
Study NCT02650206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Victoza (liraglutide) with dietician monitoring
Description: Victoza (liraglutide), an FDA-approved medication, is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Subjects with this intervention will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
Study NCT02650206 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo with dietician monitoring
Description: Subjects will not receive the study drug, but will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
Study NCT01209286 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Blinatumomab
Description: Continuous intravenous infusion over four weeks per treatment cycle
Study NCT01920178 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PinPointe Foot Laser
Description: Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
Study NCT01920178 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PinPointe Foot Laser
Description: Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
Study NCT04252170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation Therapy, Experimental on the BrightArm Compact device
Description: Experimental group will receive VR game-based rehabilitation therapy through Bright Cloud's proprietary device, called BrightArm Compact (BAC). An Occupational Therapist will assist as needed.
Study NCT02218775 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2456302
Description: Mood and Anxiety Disorders
Study NCT01808521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well tolerated, 150mb/kg over 17 hours
Study NCT02245750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hysteroscopy
Description: hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
Study NCT04255654 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Intervention for Food Insecurity
Description: 2 item screening tool (brief intervention)
Study NCT01708005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lecitone®Se-Vitamin D3
Description: Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form.~Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
Study NCT01708005 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
Study NCT01068223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A:JNJ-39758979/Placebo #1
Description: Single oral dose of JNJ-39758979 600 mg and Placebo
Study NCT01068223 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: C:Cetirizine/JNJ-39758979 Matching Placebo
Description: JNJ-39758979 Matching Placebo and Placebo #2
Study NCT01068223 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: B: JNJ-39758979 Matching Placebo /Placebo #2
Description: A single dose of 2 different Placebos
Study NCT00984698 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Social Rhythm Group Therapy
Description: 12 weeks, 2h structured group therapy
Study NCT00984698 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Present Centered Group Therapy
Description: 12 weeks, 2h relatively unstructured group therapy
Study NCT00847158 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: phacoemulsification alone
Description: phacoemulsification alone
Study NCT00847158 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iStent Trabecular Micro-Bypass Stent
Description: phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
Study NCT05211453 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: atrioventricular node ablation
Description: atrioventricular node ablation
Study NCT00596258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-007
Description: applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
Study NCT01372683 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Comparison of oat based breakfast cereals
Study NCT00246610 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir mesylate, 625 mg
Description: Nelfinavir 625 mg \[dosed orally as 1250 mg BID (two 625 mg tablets given orally BID)\] plus Combivir (lamivudine 150 mg plus zidovudine 300 mg BID dosed orally) administered with food. Subjects will start treatment at their baseline visit. Subjects will be treated for up to 26 weeks during pregnancy plus 6 weeks postpartum.
Study NCT04445519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX 470 0.065% (initial phase of trial)
Description: NCX 470 Ophthalmic Solution, 0.065% (initial phase of trial)
Study NCT04445519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% (initial phase of trial)
Description: Latanoprost Ophthalmic Solution, 0.005%
Study NCT04445519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX 470 0.1% (initial phase of trial)
Description: NCX 470 Ophthalmic Solution, 0.1%
Study NCT04445519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NCX 470 0.1% (remainder of trial)
Description: NCX 470 Ophthalmic Solution, 0.1%
Study NCT04445519 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Latanoprost 0.005% (remainder of trial)
Description: Latanoprost Ophthalmic Solution, 0.005%
Study NCT04208321 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VT-1598
Description: VT-1598 is a novel oral agent for the treatment of fungal infections. It will be supplied as 40 mg and 80 mg tablets.
Study NCT01683643 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SBIRT
Description: Screening, brief intervention, and referral to treatment.
Study NCT01683643 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
Study NCT00961610 — intervention group
Intervention type: BEHAVIORAL
Intervention: Internet peer-support group
Description: The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.~All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.~The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date.
Study NCT03542591 — intervention group
Intervention type: OTHER
Intervention: Questionnaire on the topic Supplementation of critical nutrients in a plant-based diet
Description: No active intervention, only survey as mentioned above.
Study NCT02167048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psychostimulants
Description: Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions.
Study NCT02167048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychostimulants
Description: Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions.
Study NCT01040923 — intervention group
Intervention type: DEVICE
Intervention: CardioSond Cardiac Sonospectrographic Analyzer
Description: The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
Study NCT01792778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ViaValve Safety IV Catheter
Description: Insertion of the peripheral intravenous catheters into both upper extremities of subjects
Study NCT01792778 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Insyte Autoguard BC [Blood Control] Shielded IV Catheter
Study NCT03936764 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Preoperative Pulmonary Rehabilitation
Description: Each prehabilitation session will last approximately 90 minutes and will include:~* Endurance training at the ventilatory threshold, determined according to the initial CPET. The first session will last for 15 to 20 minutes then increase by 5 minutes each session to reach 45 minutes in total (including a 5-minute warm-up and 5 minutes of active recovery). The intensity will then increase by 5 or 10 W, as could be tolerated;~* Peripheral muscle strengthening at 60% to 70% of the 1-repetition maximum of 3 main components (quadriceps press, whole-leg extension, and upper limb pull down). Three sets of 12 movements will carry out for each exercise and the load will increase weekly as tolerated;~* Inspiratory muscle training using a threshold calibrated to at least 30% of the MIP. Patients will be encouraged to carry out 15 minutes of independent training daily and to increase the resistance regularly.~* Education to bronchial drainage techniques as well as directed coughing.
Study NCT00949221 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE
Description: * group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;~* group 2: intensive strategy using continuous glucose monitoring for 12 months;~* group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring).
Study NCT03524950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Ninety patients will be assigned to three groups. Group A add saline in general anesthesia laparoscopic hysteromyoma surgery. Group B add dexmedetomidine 1μg/Kg10minutes as loading dose, followed by 0.7μg/Kg/h for maintenance.Group C add dexmedetomidine 0.7μg/Kg10minutes as loading dose, followed by 0.5μg/Kg/h for maintenance.
Study NCT01203956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SmartFlex
Description: Device used with smartflex engaged.
Study NCT01203956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard
Study NCT02176902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Receive dietary counseling
Study NCT02176902 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral dietary intervention
Description: Receive guidelines for low-fat diet
Study NCT02176902 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: omega-3 fatty acid
Description: Given PO
Study NCT02176902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03630965 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPR Video
Description: A 7.07 minutes' CPR video will be administered to the ICU patients' surrogates in Group B.~After viewing the video, the surrogate will complete the Hamilton Anxiety Rating Scale, a five-question survey about CPR, and a one-question form about comfort using the Likert Scale.